Venkatasubramanian Ganesan, Chittiprol Seetharamaiah, Neelakantachar Narendran, Shetty Taranath K, Gangadhar Bangalore N
Department of Psychiatry, National Institute of Mental Health & Neurosciences, Bangalore, India.
Clin Neuropharmacol. 2010 Nov-Dec;33(6):288-92. doi: 10.1097/WNF.0b013e3181fa2a6f.
The study objective was to explore the biological basis for link between antipsychotic-induced weight gain and therapeutic response in schizophrenia by examining longitudinal changes in serum leptin level after antipsychotic treatment.
We examined serum leptin in schizophrenia patients at antipsychotic-naive baseline status as well as after 3 months of antipsychotic treatment. For baseline analyses, the patients were compared with healthy controls matched for anthropometric measures and physical activity.
At baseline, schizophrenia patients had significantly lower levels of leptin in comparison with controls. After treatment, body mass index and levels of leptin increased significantly in patients. The magnitude of increase in leptin had a significant positive correlation with magnitude of increase in body mass index; the magnitude of reduction in SANS total score showed significant positive correlation with the magnitude of increase in leptin level.
The study findings suggest a potential role for leptin to mediate the link between antipsychotic-induced weight gain and beneficial therapeutic response in schizophrenia.
本研究的目的是通过检测抗精神病药物治疗后血清瘦素水平的纵向变化，探讨精神分裂症患者抗精神病药物所致体重增加与治疗反应之间联系的生物学基础。
我们检测了精神分裂症患者在未使用抗精神病药物的基线状态以及抗精神病药物治疗3个月后的血清瘦素水平。在基线分析中，将患者与在人体测量指标和身体活动方面相匹配的健康对照者进行比较。
在基线时，精神分裂症患者的瘦素水平显著低于对照组。治疗后，患者的体重指数和瘦素水平显著升高。瘦素升高的幅度与体重指数升高的幅度呈显著正相关；阴性症状评定量表总分降低的幅度与瘦素水平升高的幅度呈显著正相关。
研究结果提示瘦素可能在介导精神分裂症患者抗精神病药物所致体重增加与有益治疗反应之间的联系中发挥作用。
